| Primary information |
|---|
| sequence ID | Seq_7718 |
| Peptide sequence | SSSYSKQFTSSTSYNRGDSTFESKSYKM |
| CancerPDF_ID | CancerPDF_ID15, CancerPDF_ID1032, CancerPDF_ID1268, CancerPDF_ID1284, CancerPDF_ID8519, CancerPDF_ID9728, CancerPDF_ID12728, CancerPDF_ID12761, |
| PMID | 16896061,16395409,21136997,21136997,23667664,21533267,27058005,26282206 |
| Protein Name | Fibrinogen alpha chain,Fibrinogen alpha chain,Fibrinogen alpha,Fibrinogen alpha,Fibrinogen alpha,Fibrinogen alpha chain,Fibrinogen alpha chain,"FGA, Isoform 2 of Fibrinogen alpha chain" |
| UniprotKB Entry Name | FIBA_HUMAN,FIBA_HUMAN,FIBA_HUMAN,FIBA_HUMAN,FIBA_HUMAN,FIBA_HUMAN,FIBA_HUMAN,FIBA_HUMAN |
| Fluid | Serum,Serum,Serum,Serum,Serum,Serum,Serum,Serum |
| M/Z | 3190.4,3190.4,3189.41969,3205.4146,3189.42,798.36,3206.443,3210 |
| Charge | 1,1,1,1,1,4,NA,NA |
| Mass (in Da) | 3190.42,NA,NA,NA,3192.4,NA,NA,NA |
| fdr | NA,NA,NA,NA,NA,NA,NA,NA |
| Profiling Technique | MALDI-TOF,MALDI-TOF,LC-MS,LC-MS,MALDI-TOF,LC-MS,MALDI-TOF,MALDI-TOF |
| Peptide Identification technique | Q/TOF MS/MS,Q/TOF/TOF and LC-MS/MS,LC-MS-MS/MS,LC-MS-MS/MS,FT-ICR MS/MS + nano-HPLC,LC/MS/MS,LC-MS/MS,nano-LC/ESIeMS/MS |
| Quantification Technique | NA,NA,LC-ESI-MS,LC-ESI-MS,NA,Multiple Reaction Monitoring,NA,NA |
| Labelled/Label Free | Label Free,Label Free,Label Free,Label Free,Label Free,Label Free,Label Free,Label Free |
| FDR | NA,less than 1 “5,NA,NA,NA,1.49,NA,NA |
| CancerPDF_ID | CancerPDF_ID15, CancerPDF_ID1032, CancerPDF_ID1268, CancerPDF_ID1284, CancerPDF_ID8519, CancerPDF_ID9728, CancerPDF_ID12728, CancerPDF_ID12761, |
| p-Value | 1.00E-05,3.76E-07,NA,NA,NA,NA,"less than 0.01,0.623,0.743",NA |
| Software | MASCOT,MASCOT (v 2.0.04 for Windows),MASCOT(v. 2.2.01),MASCOT(v. 2.2.01),MASCOT,MASCOT,Proteome Discoverer,BioworksBrowser |
| Length | 28,28,28,28,28,28,28,28 |
| Cancer Type | Metastatic thyroid carcinomas,"Advanced Prostate, Breast and Bladder cancer",Colorectal cancer,Colorectal cancer,"Breast cancer, Lung cancer, Rectal cancer",Lung adenocarcinoma,Breast cancer,Cervical cancer |
| Database | NCBI refseq Protein Database,NCBI refseq Protein Database,SwissProt Database,SwissProt Database,NA,Swissprot Database (57.4),SwissProt Database,IPI Human Database (3.45) |
| Modification | NA,NA,NA,Oxidation of Met,NA,NA,Oxidation (M),NA |
| Number of Patients | 40 metastatic thyroid carcinoma patients and 40 normal for training phase and 10 metastatic thyroid carcinoma and 10 normal individuals for independent validation,"Advanced prostate (n = 32), breast (n = 21), and bladder (n = 20) cancer, 33 healthy",30 patients and 30 healthy controls,30 patients and 30 healthy controls,"Breast Cancer =84, lung cancer= 70, Rectal cancer = 30patients; 500 healthy",62 lung adenocarcinoma and 30 healthy control," 28 were diagnosed with Breast cancer, 27 remained cancer-free with BRCA carrier. Of the remaining patients, 39 were diagnosed with sporadic breast cancer (SBC), and 38 were healthy volunteers (WT).",35 SCC patients (Cervical squamous cell carcinoma) and 20 healthy controls |
| Regulation | Differentially expressed between cancer vs normal samples,"Downregulated in cancer vs normal with Ratio of median intensity (patients/Controls) = 0.52, 0 and 0.94 in prostate, bladder and breast cancer respectively",NA,NA,NA,"Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal","Upregulated with the fold change of 1.44 in breast cancer vs Cancer free patients with brca mutation, Upregulated in breast cancer vs sporadic breast cancer with fold change of 1.05, Upregulated in BC vs healthy with 0.958 fold change",Downregulated in Cervical squamous cell carcinoma vs healthy |
| Validation | Independent validation,Independent validation,Leave One out Cross validation,Leave One out Cross validation,NA,MRM-based validation of 19 candidates,NA,NA |
| Sensitivity | 95% on independent dataset,97.5% for multiclass and 100 % for binary classification system on independent validation dataset,NA,NA,NA,NA,NA,100 % on traning data and 80% on validation dataset |
| Specificity | 95% on independent dataset,NA,NA,NA,NA,NA,NA,100% on training data and 100% on validation dataset |
| Accuracy | NA,97.5 % on validation dataset,NA,NA,NA,NA,NA,NA |
| Peptide Atlas | NA |
| IEDB | |